Clinical Trials Bottleneck: Culture, Regulation, and Innovation Stalled
2024-12-20
This blog post explores the high costs and inefficiencies of clinical trials. The authors argue the root problem lies in industry culture—an overemphasis on safety that neglects the risks of inaction. This leads to regulatory overreach, such as restrictions on patient compensation and slow adoption of innovative methods (like risk-based monitoring). The post calls for a cultural shift, increased transparency, and policy adjustments to incentivize innovation, ultimately speeding up drug development.
Read more